The United States federal health agencies on Tuesday recommended pausing the use of Johnson & Johnson’s single-dose COVID-19 vaccine. This is after six recipients developed a rare disorder involving blood clots.
The U.S. Centre for Disease Control and Prevention will hold an advisory meeting on Wednesday to review the cases.
All the six recipients were women between the ages of 18 and 48. One woman died and a second in Nebraska has been hospitalized in critical condition, the New York Times reported.
The CDC and the U.S. Food and Drug Administration said in a joint statement that the adverse events appear to be extremely rare right now.
As of April 12, more than 6.8 million doses of the Johnson & Johnson vaccine have been administered in the United States.
READ MORE
Why US is experiencing largest measles outbreak
From wagging tails to healthy tales: How pets improve mind and body
From Monkey pox, Covid-19 and Nipah virus: Why animal-to-human diseases are on the rise
EAC launches first regional framework to strengthen pandemic preparedness
The company’s shares were down 3% before the opening bell.
The move from the U.S. regulators comes less than a week after Europe’s drugs regulator said it was reviewing rare blood clots in four people in the United States who received the shot.
